© Medical Review Institute of America LLC. All rights reserved.

Please complete the information below to download the content.

The specialty drug market represents approximately 50% of total drug cost in the United States today, leading to ongoing scrutiny over spending in this area.1 Though specialty drugs create innovative treatment options and introduce technological advances into clinical practice, their overwhelming costs often pose high risk to healthcare sustainability.

To overcome this barrier, the healthcare utilization management organization Medical Review Institute of America (MRIoA) provides evidence-based medical reviews to support innovative treatments in healthcare and ensure patients have access to the right treatment while also controlling costs.